|Bid||0.00 x 1400|
|Ask||0.00 x 1000|
|Day's Range||96.50 - 102.84|
|52 Week Range||50.71 - 102.84|
|Beta (3Y Monthly)||1.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||92.43|
Shares of Seattle Genetics entered the triple-digit club Monday after the biotech company improved upon a breast cancer treatment from Roche. Seattle stock is now in a profit-taking zone.
Boeing got crushed by sellers again, weighing on the Dow Jones Industrial Average. But the stock market today showed bullish moves in the medical field.
(Bloomberg) -- As Seattle Genetics Inc. rallies on a successful breast cancer study Monday, the biotech’s largest holder, Baker Bros. Advisors LP, stands to gain nearly $730 million on the day from its stake.The investment firm founded by Felix and Julian Baker made a big bet in the company, their biggest in fact, with a 29% stake, as of June 30, according to data compiled by Bloomberg. That stake is worth roughly $5 billion today after tucatinib -- an experimental therapy Seattle Genetics acquired for more than $400 million last year -- surprised investors by slowing the spread cancer and extending patients’ lives. Even more surprisingly, it had an effect on patients whose cancer had spread to their brains. Baker Bros. has been invested in the company for over 15 years, and Felix Baker is a lead director for the biotech. Today Seattle Genetics makes up over 28% of Baker Bros.’s $15.5 billion in assets.The stock rose as much as 17% to a record high of $101.95 intraday. Twelve analysts that follow the company rate it the equivalent of a buy, five rate it a hold and one rates it a sell. With an average price target of $87, some analyst target raises are likely in the near future.To contact the reporter on this story: Cristin Flanagan in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Catherine Larkin at email@example.com, Jennifer Bissell-LinskFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seattle Genetics Inc. shares soared 15% Monday, after the company announced positive results in a trial of a treatment for breast cancer. Bothell, Wash.-based Seattle Genetics said the trial of tucatinib in locally advanced or metastatic HER2-positive breast cancer met its primary endpoint of progression-free survival. Patients were treated with tucatinib in combination with trastuzumab and capecitabine to trastuzumab and capecitabine alone. The trial also met its secondary endpoints. "Based on these findings, we plan to unblind the trial and offer tucatinib to patients on the control arm," Chief Medical Officer Roger Dansey said in a statement. The company is also planning to submit a New Drug Application to the FDA in the first quarter of 2020, he said. HER2-positive breast cancer is an aggressive form of the disease that affects 15% to 20% of cases worldwide. The trial is expected to enroll about 460 patients in North America, Europe and Asia. Leerink analysts said the trial is another win for Seattle Genetics and a "near best-case scenario." They reiterated their outperform rating on the stock. Shares have gained 76% in 2019, while the S&P 500 has gained 19%.
Shares of the large-cap biopharma Seattle Genetics, Inc. (NASDAQ: SGEN ) were advancing strongly Monday following a clinical trial readout from the company. Primary, Secondary Endpoints Met A pivotal ...
Shares of Seattle Genetics rose as much as 16% Monday after the company announced positive results from a trial of its oral breast cancer treatment, tucatinib. The trial involved tucatinib with a combination of other medicines in patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2, or HER2, breast cancer, which leads to the aggressive spread of cancer cells. "The addition of tucatinib to the commonly used doublet of trastuzumab and capecitabine represents a potential significant clinical advance for patients with metastatic HER2-positive breast cancer, importantly, including those with brain metastases," Roger Dansey, a physician who is chief medical officer at Seattle Genetics, said in a release.
-HER2CLIMB Trial Met Primary Endpoint and Both Key Secondary Endpoints-
Here are four stocks positioned right at key technical breakout points. Horizon Therapeutics PLC (HZNP) climbed 92 cents to $28.20 on 2.3 million shares traded Tuesday, more than 1 1/2 times its average volume. The move, which came on no news from the drug maker targeting treatments for rare and rheumatic diseases, edged the stock out of a two-month sideways channel.
By Harry Boxer, TheTechTrader Here are four stocks positioned right at key technical breakout points. Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) climbed 92 cents to $28.20 on 2.3 million ...
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]
Seattle Genetics (SGEN) doses the first patient in the phase III HER2CLIMB-02 study on tucatinib in combination with Roche's Kadcyla for treating advanced/metastatic HER2-positive breast cancer.
Seattle Genetics' (SGEN) only marketed product, Adcetris, has been performing well since its launch. The company's established pipeline candidates are also progressing well.
Seattle Genetics, Inc. today announced dosing of the first patient in HER2CLIMB-02, a randomized phase 3 clinical trial evaluating investigational agent tucatinib versus placebo, in combination with standard-of-care ado-trastuzumab emtansine , for patients with locally advanced or metastatic HER2-positive breast cancer.
Seattle Genetics, Inc. announced today that it will report its third quarter 2019 financial results on Tuesday, October 29, 2019 after the close of financial markets.
A recession could be headed your way, warns Goldman Sachs -- and that's okay.In a recent report, Goldman private wealth management chief investment officer Sharmin Mossavar-Rahmani put the chances of a recession hitting the U.S. in 2020 at somewhere between 25% and 30% -- triple the risk seen three years ago. Despite the risk, though, there's also still opportunity to profit from owning the right companies.Jobs numbers in the U.S. remain strong. GDP growth is expected to end this year at 2.3%, then slow in 2020, but still remain above 2% -- not negative at all. And in the event a recession does not occur, 86% of the time, says Mossavar-Rahmani, stocks continue to go up!So which stocks does Goldman Sachs recommend that you buy "just in case?"Utilizing the Stock Screener at TipRanks, We've found three stocks receiving "buy" ratings from most analysts in general, and endorsed by Goldman Sachs in particular. Let's take a closer look:Stitch Fix (SFIX)Stitch Fix is a clothing by mail subscription service, mailing its customers monthly deliveries of clothes, shoes, and accessories, which customers can then peruse and either accept (and pay for) or mail back (and not). But while the business model may bear a whiff of "Columbia House CDs," it's doing a whole lot better than its predecessor in concept.With profit margins intact, guiding for 11% to 13% EBITDA margins, 5-star Goldman Sachs analyst Heath Terry sees SFIX stock as attractively priced "below the ecommerce sector average despite faster revenue and EBITDA growth." Terry rates Stitch Fix a 'buy' with a $24 price target -- implying 20% upside from today's prices. (To watch Terry's track record, click here)Terry points out, Stitch Fix nailed analyst estimates with sales of $432 million. Adjusted for a slightly longer quarter than Q4 2018 had in it, the analyst says grew 26% year over year, and management's "FY20 revenue guidance of +20.5% -22.5% ... bracketed consensus" expectations as well.Client rolls are expanding at a "stable" rate, "spend per client" is also growing nicely, and the company is expanding its business both internationally (to the UK) and categorically, as Stitch Fix promotes subscriptions for children's clothing.When looking at Wall Street’s stance, Terry is not the only bull, as TipRanks analytics showcase SFIX as a Buy. Out of 9 analysts polled in the last 3 months, 5 rate SFIX a 'buy', while 4 say 'hold'. The 12-month average price target stands at $26.89 marking an 37% upside from where the stock is currently trading. (See SFIX's price targets and analyst ratings on TipRanks)Wynn Resorts (WYNN)Not interested in "gambling" on whether consumers will take a fancy to clothing subscriptions? Perhaps a more straightforward gambling play is more to your taste? Here, Goldman analyst Stephen Grambling offers up Wynn Resorts, the Las Vegas-based casino operator that now gets 75% of its revenues from the island of Macau in... China!At present, more than half of Wynn's physical assets still call the United States home, and the company is investing heavily in "major capital projects" in Boston and Las Vegas, which have been a drain on cash. But as Grambling points out, free cash flow at Wynn "is set to inflect" as these projects come to completion, even as the company's Macau properties have "potential for upside," helping to pull Wynn stock up from a "near-trough valuation" to as high as $155 a share. (To watch Grambling's track record, click here)Indeed, of all the casino operators that Goldman Sachs covers, Grambling believes Wynn has the best potential for upside -- as much as 46%, versus 33% for Las Vegas Sands for example. With a 14-ish P/E ratio and a 14%-ish projected earnings growth rate on the Street -- and a strong 3.6% dividend yield to boot -- the analyst believes Wynn is poised to outperform.Overall, Wall Street sizes up Wynn Resorts as a ‘Moderate Buy’ stock, as the bulls edge out the cautious on the Las Vegas gaming and hospitality giant. In the last 3 months, WYNN has received 7 bullish ratings versus 3 analysts hedging their bets. The 12-month average price target of $135.20 reflects a potential upside of 24%. (See WYNN's price targets and analyst ratings on TipRanks)Seattle Genetics (SGEN)Switching gears (rather dramatically I should say) from consumer-focused stocks to the bright, shiny new world of biotech, Goldman Sachs' third buy-rated pick today is Seattle Genetics, a rising force in the world of oncology.Goldman Sachs analyst Salveen Richter rates SGEN a "buy" with a $100 price target (the stock costs $84 today) on hopes that increased use of Advetris to treat Hodgkin's lymphoma and peripheral T cell lymphoma will prove to be "pipeline drivers to cement SGEN's transition into a multi-product oncology company." (To watch Richter's track record, click here)Richter further expects new drugs enfortumab vedotin to receive FDA approval as early as March 2020, and is "positive" on the prospects for two more drugs in late-stage clinical trials, "tucatinib" for treating metastatic breast cancer and tisotumab vedotin for use against metastatic cervical cancer. Those clinical results are due out before the end of this year, and in the first half of next year, respectively. And Seattle Genetics has a nice pipeline of similarly tongue-twisting drug candidates waiting in line behind those.In terms of dollars and cents, of course, there's little here to attract value investors. At least, Richter doesn't see any potential for GAAP profits through at least 2021. (On the other hand, the consensus on Wall Street is that S-Gen will in fact earn a profit in 2021). Whichever way things play out on the profit front, revenue growth alone may be enough to support Seattle Genetics stock, with Richter projecting a rough doubling in sales to $1.29 billion by 2021.That's good enough for a "buy" rating in Goldman Sachs' estimation -- and a 19% profit for investors buying at today's prices.The initial word out on the Street echoes Richter's bullish conviction on the drug maker, as TipRanks analytics showcase SGEN as a Buy. Based on 15 analysts polled in the last 3 months, 10 are bullish on the stock, while 4 remain sidelined and one (Merrill Lynch) is bearish. (See SGEN's price targets and analyst ratings on TipRanks)
Immunomedics (IMMU) presents interim data on sacituzumab govitecan in patients with metastatic urothelial cancer. The company also inks two deals.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Viveve Medical (NASDAQ: VIVE ) shares were ...
Seattle Genetics (SGEN) and Astellas' enfortumab vedotin in combination with Merck's Keytruda proves safety in a phase I study as a first-line treatment for advanced bladder cancer. Shares up.
Seattle Genetics stock broke out bullishly Monday after the biotech company presented "striking" results for a bladder cancer treatment. Its colon cancer treatment also impressed analysts.
At a cancer-medicine conference in Barcelona this week, researchers presented data. There was new evidence for rival immunotherapies from Merck and Bristol-Myers Squibb. Seattle Genetics bested Immunomedics in treating bladder cancer. Amgen suffered a disappointment.
The five-day European Society of Medical Oncology, or ESMO, Congress 2019 is set to conclude Tuesday in Barcelona, Spain. Touted as a congress where the exchange of translational cancer science of excellence ...
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Dova Pharmaceuticals (NASDAQ: DOVA ) shares ...